Chemotherapy based on liposomal doxorubicin (Myocet ® ) in metastatic breast cancer after prior first-line treatment with anthracycline

Abstract

Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant therapeutic problem. The abundance of available systemic treatment regimens and the possibility of applying different therapies pose before the physician a difficult task of employing the optimal treatment approach. At the same time, good therapeutic results and ever better tolerance for systemic treatment lead to female patients receiving a large number of chemotherapy lines. One of the options in recent years is the treatment with the use of liposomal doxorubicin. A case report is presented of a female patient who received secondline therapy with liposomal doxorubicin in combination with cyclophosphamide after prior treatment with anthracyclines.
Onkol. Prak. Klin. 2010; supl. A: A28–A30